China's biomedical regional imbalance further widening

Business News Agency June 8th Recently, CCID Consulting, a well-known consulting company, published the “White Paper on China's Biomedical Industry Map (2011)” in Beijing, which announced the status of the development and deployment of the biomedical industry in China, and the distribution and development of the industry in the future. Trends are forecasted. According to the white paper, at present, the distribution of China's biomedical industry clusters has become even more apparent, and an industrial spatial pattern with the rapid development of the Yangtze River Delta, Bohai Rim, Pearl River Delta, Northeast China and other central and eastern regions has preliminarily been formed. However, the unbalanced regional development will further highlight the gap between the eastern coastal areas and the central and western regions will continue to widen. The R&D factors will further converge in Shanghai and Beijing, and the manufacturing sector will accelerate its accumulation in Jiangsu and Shandong.

Xiao Jinsong, director of CCID Consulting's government consulting group, said that due to the high investment, high risk, high returns, and long development cycle of biomedicine, the industry must achieve three major agglomerations: agglomeration in industrial parks and accumulation in economically developed areas. Gathered to areas of specialized intellectual concentration. "The "12th Five-Year Plan" period, China's bio-pharmaceutical industry will continue to be concentrated in the eastern coastal areas of scientific research institutes concentrated and innovative ability of the provinces, and a small number of central and western cities, regional development imbalances have further strengthened the trend. Xiao Jinsong said.

Through empirical analysis of the development of biopharmaceuticals in the United States, the United Kingdom, Japan, and other countries, the strong support of national policies, the improvement of independent innovation systems, the obvious effect of leading companies, the mature funding operation model, and the close integration of the new generation of information technologies are the development of the biopharmaceutical industry. The key factor for success.

The white paper suggests that in the future, the pattern of China's biopharmaceutical industry should establish a scientific assessment system, carry out regional overall planning, promote the accumulation of advantageous resources, and encourage cooperation in professional division of labor. Improve the campus hardware and software environment and guide the development of enterprise clusters.

“The government should strengthen the macro-guidance of regional and provincial biopharmaceutical industry development, scientifically compile biopharmaceutical industry plans, establish access standards, coordinate industrial layout and regional division of labor, and avoid low-level redundant construction and vicious competition,” Xiao Jinsong said.